Although anti-VEGF therapy is the current gold-standard treatment for retinal vein occlusion, not all patients respond to it. A study has found that volume of intraretinal fluid, among other factors detectable with optical coherence tomography, may help predict treatment response.
Even Brief Delays in Intravitreal Injection Can Cause Vision Loss
Patients with diabetic eye disease or vein occlusion lost more vision than patients with age-related macular degeneration when they missed an intravitreal injection during the COVID-19 shutdown.
Retinal Leakage Pattern and Vascular Tortuosity May Predict Durability of Anti-VEGF Therapy
Study associates leakage patterns and tortuosity in retinal blood vessels with anti-VEGF therapy interval tolerance in patients with diabetic eye disease or retinal vein occlusion.
Predicting Visual Acuity Response to Anti-VEGF Therapy in Macular Edema Secondary to Retinal Vein Occlusion
Study shows that baseline presence of and changes in DRIL burden during the course of disease in RVO is a useful prognostic indicator for VA and can help guide treatment with anti-VEGF therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy